Request Demo

Last update 10 Jul 2025

Latanoprost

Last update 10 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

L-PPDS, AL-37807, AR-202

+ [29]

Target

PTGFR

Action

agonists

Mechanism

PTGFR agonists(Prostanoid FP receptor agonists)

Therapeutic Areas

Eye Diseases

Active Indication

GlaucomaGlaucoma, Open-AngleOcular Hypertension+ [2]

Inactive Indication

Corneal DiseasesExfoliation SyndromeGlaucoma, Angle-Closure+ [1]

Originator Organization

Pfizer Inc.

Active Organization

Orimed Pharma, Inc.Santen OyThea Pharma, Inc.

+ [7]

Inactive Organization

Santen Pharmaceutical Co., Ltd.Santen SAS

Sun Pharmaceutical Industries Ltd.

+ [1]

License Organization

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Viatris, Inc.

Inter Pharma PCL

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (05 Jun 1996),

Glaucoma, Open-AngleOcular Hypertension

Regulation-

Structure/Sequence

Molecular FormulaC26H40O5

InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N

CAS Registry130209-82-4

189

Clinical Trials associated with Latanoprost

NCT07016113

/ Not yet recruitingPhase 2IIT

Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children

Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.

Start Date01 Jul 2025

Sponsor / Collaborator

Universitas Padjadjaran

NCT06964061

/ RecruitingPhase 1

An Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Biodegradation Period of PA5346 Ocular Implant, 115mcg When Administered to Patients With Open-Angle Glaucoma or Ocular Hypertension

The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. It will also assess how long it takes for PA5346 Ocular Implant to dissolve in the eye.

Start Date10 Jun 2025

Sponsor / Collaborator

PolyActiva Pty Ltd.

NCT06964191

/ RecruitingPhase 2

A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular Hypertension

The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.

Start Date31 May 2025

Sponsor / Collaborator

PolyActiva Pty Ltd.

100 Clinical Results associated with Latanoprost

100 Translational Medicine associated with Latanoprost

100 Patents (Medical) associated with Latanoprost

2,551

Literatures (Medical) associated with Latanoprost

31 Dec 2025·DRUG DELIVERY

Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma

Article

Author: Garcia-Martin, Elena ; Bravo-Osuna, Irene ; Martínez-Rincón, Teresa ; Munuera, Inés ; Rodrigo, María J. ; Pablo, Luis E. ; Ana González-Cela-Casamayor, Miriam ; Prats-Lluís, Catalina ; Brugnera, Marco ; Villacampa, Pilar ; Herrero-Vanrell, Rocío ; García-Feijoo, Julián

Glaucoma is a multifactorial neurodegenerative disease that affects the retina and optic nerve. The aim of this work was to reach different therapeutics targets by co-encapsulating three neuroprotective substances with hypotensive (latanoprost), antioxidant (melatonin) and anti-inflammatory (ketorolac) activity in biodegradable poly (lactic-co-glycolic acid) (PLGA) microspheres (MSs) capable of releasing the drugs for months after intravitreal injection, avoiding the need for repeated administrations. Multi-loaded PLGA MSs were prepared using the oil-in-water emulsion solvent extraction-evaporation technique and physicochemically characterized. PLGA 85:15 was the polymer ratio selected for the selected formulation. Tri-loaded MSs including vitamin E as additive showed good tolerance in retinal pigment epithelium cells after 24 h exposure (>90% cell viability). The final formulation (KMLVE) resulted in 33.58 ± 5.44 µm particle size and drug content (µg/mg MSs) of 39.70 ± 5.89, 67.28 ± 4.17 and 7.51 ± 0.58 for melatonin, ketorolac and latanoprost respectively. KMLVE were able to release in a sustained manner the three drugs over 70 days. KMLVE were injected at 2 and 12 weeks in Long-Evans rats (n = 20) after the induction of chronic glaucoma. Ophthalmological tests were performed and compared to not treated glaucomatous (n = 45) and healthy (n = 17) animals. Treated glaucomatous rats reached the lowest intraocular pressure, enhanced functionality of bipolar and retinal ganglion cells and showed greater neuroretinal thickness by optical coherence tomography (p < 0.05) compared to not treated glaucomatous rats at 24 weeks follow-up. According to the results, the tri-loaded microspheres can be considered as promising controlled-release system for the treatment of glaucoma.

31 Dec 2025·DRUG DELIVERY

Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid

Article

Author: Lee, Soomin ; Jung, Mi-Young ; Park, Choul Yong

Effective topical drug delivery is crucial for glaucoma treatment, necessitating more convenient methods to enhance patient compliance. This study evaluates the efficacy and safety of using freeze-dried hyaluronic acid (HA) as a carrier for a novel conjunctival-contact drug delivery system. We developed HA tablets loaded with latanoprost (HA-latanoprost) and verified the concentration using high-performance liquid chromatography. Twenty mice (C57BL6) were divided into four groups (n = 5 per group): normal saline (group 1), control HA tablet (group 2), Xalatan™ (group 3), and HA-latanoprost tablet (group 4). Treatments were administered to the right eyes, with the left eyes serving as no-treatment controls. Intraocular pressure (IOP) and irritation (measured by scratching motions) were monitored for 10 days. On day 10, we quantified gene expression of inflammatory cytokines and IOP-affecting proteins using polymerase chain reaction, and performed histological and immunohistochemical analyses. Results showed that IOP was significantly lower in groups 3 and 4 compared to the other groups, with group 4 exhibiting the greatest reduction by day 10. Group 4 also experienced less irritation. Additionally, group 4 had lower expression of inflammatory cytokine genes and higher expression of IOP-lowering protein genes compared to group 3. No significant side effects were observed in any group. Overall, HA-latanoprost effectively lowered IOP and reduced ocular irritation more than latanoprost eyedrops in mice. However, these results are based on animal testing, so further development is needed for clinical use.

01 Jul 2025·Drug Delivery and Translational Research

In vitro tear replenishment system: assessing drug delivery from contact lens biomaterials through corneal epithelial monolayer and multilayer under replenishment conditions

Article

Author: Gorbet, Maud ; Mohammadi, Saman ; Eslami, Shahabedin ; Jones, Lyndon

Abstract:

There is a need to develop improved in vitro ocular models for biocompatibility and drug delivery studies to assess the potential of in vivo performance of contact lenses. By using an in vitro corneal epithelial cell model combined with a tear replenishment method, this study aimed to investigate the delivery of the glaucoma drug latanoprost from contact lenses and compare the dynamic release results to no-replenishment (immersion) conditions. Corneal epithelial cells were grown as a monolayer or multilayer on curved cellulose cell culture inserts. Three contact lens materials (balafilcon A; senofilcon A; etafilcon A), soaked for 24 h in latanoprost, were placed on the curved cornea models (CCM) and drug concentration was determined on the basal (diffusion/transport) and apical (supernatant) sides after 1, 4, 8 and 12 h. The in vitro tear replenishment was achieved via intermittent flow of a tear solution over the CCM at a rate of 1 mL/hour. A zero-order kinetic was observed for basal drug concentration over the 12 h period. Similar basal and apical drug concentrations were observed with monolayer and multilayer CCM, except for the etafilcon A material. The apical release of latanoprost was significantly lower under replenishment compared to no-replenishment conditions. These results demonstrate the role that a dynamic release model will have in predicting the amount of drug that can be released from a contact lens into the tear film and the critical role of a cell monolayer in in vitro drug delivery studies.Graphical Abstract

News (Medical) associated with Latanoprost

02 Jul 2025

·www.globenewswire.com

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

June 30, 2025 – release at 7:30 am CET Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, its lead compound, in patients with open-angle glaucoma or ocular hypertension. With this milestone reached, all patients have now completed their treatment and follow-up visits. A total of 696 patients were enrolled in the trial and topline results are expected mid-August to mid-September 2025. “Reaching the milestone of the last patient last visit in the Denali Phase 3 trial is a great achievement by our clinical sites, our partner Ocumension and the Nicox development team who have continued to drive this trial. I would like to thank everyone who has been involved in the conduct of the Denali trial including our patients, investigators and their staff.” said Doug Hubatsch, Chief Scientific Officer of Nicox “We look forward to announcing the topline results in the near future, which we expect will further consolidate the profile of NCX 470 and confirm its potential in the glaucoma market. We remain fully focused on completing the clinical development program and preparing for regulatory submissions.” NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The Denali trial is evaluating the IOP lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension. It is a multi-country (U.S. and China) clinical trial financed equally by Nicox and Ocumension, Nicox’s exclusive licensee for China, Korea and Southeast Asia. The Denali trial, together with the already completed Mont Blanc trial, was designed to fulfil the clinical regulatory requirements to support New Drug Application (NDA) submissions of NCX 470 in the U.S. and China. All remaining NDA-enabling pharmacokinetic and non-clinical studies necessary to support the U.S. NDA filing are on track. Subject to securing a U.S. partner, or obtaining the necessary funding, the Company estimates that a NDA for this country NCX 470 could potentially be submitted in H1 2026. Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: Topline results are expected mid-August to mid-September 2025 NCX 470 Phase 3 clinical efficacy and long-term safety trials in Japan: Initiation expected in H2 2025 NCX 470 NDA filing in the United States: expected in H1 2026, subject to securing a U.S. partner, or obtaining the necessary funding Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa for Japan. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. The content above comes from the network. if any infringement, please contact us to modify.

NDA

11 Jun 2025

·www.businesswire.com

Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and latanoprost, the most commonly prescribed prostaglandin analogue for the treatment of glaucoma. The QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC) is being developed as a treatment for patients with primary open angle glaucoma (POAG), ocular hypertension (OHT), and normal tension glaucoma (NTG) for whom optimal intraocular pressure (IOP) control may remain unachievable due to the need to lower episcleral venous pressure (EVP). EVP, which is the target of QLS-111, remains the only component of IOP that is not addressed by currently approved treatments. QLS-111 utilizes a first-in-class ATP-sensitive potassium channel modulator designed to lower IOP by selectively reducing EVP, which may represent the largest component of IOP in patients. Latanoprost, a gold standard in glaucoma care, lowers IOP by increasing uveoscleral outflow. Together, the agents offer a complementary dual mechanism approach aimed to further enhance IOP control. Reduction of IOP remains the only modifiable risk factor shown to slow the progression to blindness in patients with glaucoma. Data from Qlaris Bio’s Phase 2 study in POAG and OHT patients, the Apteryx study, demonstrated that QLS-111, when administered in addition to latanoprost monotherapy, achieved over 3 mmHg of additional IOP reduction compared to latanoprost monotherapy alone. Importantly, this additive efficacy was achieved without additional hyperemia or other clinically meaningful adverse events, supporting the potential of QLS-111-FDC to provide improved IOP control without compromising safety or tolerability. “Patients who remain uncontrolled on monotherapy often face challenges with multi-drug therapy, which can negatively impact adherence and outcomes,” said Barbara Wirostko, MD, FARVO, Chief Medical Officer of Qlaris Bio. “A fixed-dose combination simplifies treatment regimens and, with the strong safety and additive efficacy profile of QLS-111, may offer an important option for patients requiring further IOP lowering. Importantly, the recently completed Phase 2 studies show that QLS-111 does not cause additional hyperemia, which will be important for patient compliance.” “Combining QLS-111 with latanoprost in a preservative-free fixed-dose combination is a very promising and exciting advancement,” said Alex Huang, MD, PhD, Associate Professor at the Shiley Eye Institute at UC San Diego Health. “This approach targets two distinct and complementary mechanisms and could offer improved IOP control in a single topical eyedrop—something that aligns well with real-world needs of patients surrounding compliance and long-term IOP control. Targeting the reduction of EVP and distal outflow to lower IOP represents a fundamental shift in how we think about glaucoma therapy.” About QLS-111 QLS-111 is a novel topical ATP-sensitive potassium channel modulator that reduces IOP by selectively targeting EVP. The program was originally studied in the laboratory of Prof. Michael Fautsch, PhD, at Mayo Clinic and has been developed into Qlaris Bio’s non-preserved formulation, QLS-111. Clinical studies have demonstrated that treatment with QLS‑111 provides significant IOP lowering, maintains normal vascular integrity, and is well-tolerated without added hyperemia. (Trials: NCT06016972, NCT06249152). About Qlaris Bio, Inc. Founded in 2019, Qlaris Bio is a clinical-stage biotechnology company focused on developing innovative first-in-class therapies for glaucoma. The company’s lead program, QLS-111, is designed to address a significant unmet need in glaucoma treatment by targeting EVP. For more information, please visit www.qlaris.bio.

Phase 2Clinical Result

21 May 2025

·pharma.economictimes.indiatimes.com

Sluggish sales hurt Gland Pharma FY25 earnings, Q4 net profit down 3%

Hyderabad: Injectables developer Gland Pharma Q4 FY24-25 revenue from operations reported a year-on-year decline of 7 per cent to ₹1,424 crore. While the quarter’s profit margin remained unchanged at 13 per cent against the corresponding period, the Profit After Tax (PAT) reported a decline of 3 per cent YoY and 9 per cent QoQ to ₹186 crore, down from ₹192 crore recorded in the corresponding period. On both quarter and annual basis, the Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) contracted by 3 per cent to ₹ 347 crore. For the full financial year, the company's revenue reported a margin dip of 1 per cent to ₹5,616 crore while its net profit plummeted by 10 per cent to ₹698.5 crore, down from ₹772.5 crore recorded in the previous fiscal. During the period, the company's profit margin contracted by 2 percentage points to 12 per cent. In FY25, the US business reported muted revenue growth while the revenue from Europe, India and Rest of World declined by 2 per cent, 11 per cent and 4 per cent, respectively. Of the total fiscal earnings, revenue from Gland base business declined by 1 per cent to ₹4,124 crore, while the net profit stood at ₹1,086 crore at a stable margin of 26 per cent. On a regional basis Gland’s base business revenue in the US remained flat, standing at ₹2,976 crore whereas its revenue from India contracted by 11 per cent to ₹248 crore. “FY25 was a year of strategic realignment and investment in future growth. Through the year, we mitigated many challenges and strengthened the core by advancing key pillars of manufacturing, quality, and R&D,” said Srinivas Sadu, Executive Chairman, Gland Pharma. During the period, it launched 31 molecules, including “four new molecules namely Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), in Q4 FY25. Gland Pharma also launched its first partnered GLP-1, Liraglutide, in Q4 FY25 and is working to expand its production capacity to 140 million units, up from the current 40 million units As per the company release, discussions with Henlius are progressing well and are expecting revenue generation from the collaboration with Dr Reddy’s in the ongoing fiscal. “Our progress in biologics CDMO and collaborations with leading partners reflect our intent to diversify and grow beyond traditional segments. We remain firmly focused on executing the Cenexi turnaround and leveraging targeted M&A to drive long-term, sustainable value for all stakeholders,” Sadu noted. Outlining the company’s future plans the CEO said, “Our approach involves expanding our core business into new emerging markets, building complex injectables pipeline and through our robust in-house research and development efforts.” Following the announcement of Gland quarter results, the board has recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. By Online Bureau ,

Financial Statement

100 Deals associated with Latanoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D00356	Latanoprost	S01EE01	DB00654

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Viatris, Inc.	12 Mar 1999
Glaucoma, Open-Angle	United States	Upjohn US 2 LLC	05 Jun 1996
Ocular Hypertension	United States	Upjohn US 2 LLC	05 Jun 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eye Diseases	NDA/BLA	Canada	Orimed Pharma, Inc.	01 Jan 2025
Glaucoma, Angle-Closure	Phase 2	United States	Santen SAS	01 Nov 2010
Glaucoma-Related Pigment Dispersion Syndrome	Phase 2	United States	Santen SAS	01 Nov 2010
Corneal Diseases	Clinical	Taiwan Province	Santen Pharmaceutical Co., Ltd.	02 Apr 2018
Exfoliation Syndrome	Clinical	United States	Pfizer Inc.	01 Aug 2000
Dry Eye Syndromes	Preclinical	Germany	Novaliq GmbH	15 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2023	Not Applicable	Uveal Effusion Syndrome	-	Topical Latanoprost	nzfwhipcse(wjxgpbsggr) = exacerbation of uveal effusion in nanophthalmic eyes cpxokaljgl (rsbihuapja )	-	05 Oct 2023
				Topical Corticosteroids
NCT04405245 (CTgov)	Phase 2	Glaucoma, Open-Angle	194	AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% QD + Latanoprost)	sfxdfllvtm(khmeannifl) = mauidgpgkn osvpbpvdrn (tlqoxesryv, 0.258) View more	-	25 May 2023
				AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% BID + Latanoprost)	sfxdfllvtm(khmeannifl) = csupogfhqs osvpbpvdrn (tlqoxesryv, 0.257) View more
ARVO2023	Not Applicable	Glaucoma	107	Preservative-free surfactant-free latanoprost eyedrop	pqhubelduu(euphgjhotm) = bnlcenegpw hqzjgtyagu (orecmzbwha )	-	23 Apr 2023
NCT00934089 (CTgov)	Phase 2	Glaucoma, Open-Angle	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	njzfycgtmb(ygyiuryirh) = qquknbtlrx phbjcdfsgq (zqytbceinn, 3.264) View more	-	03 May 2021
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	njzfycgtmb(ygyiuryirh) = csgbrufokq phbjcdfsgq (zqytbceinn, 2.786) View more
NCT02466399 (CTgov)	Phase 2	Glaucoma, Open-Angle	80	POLAT-001 (POLAT-001)	ckwwfhoufi(lszudghnhv) = rdalkapieg qtuevlzsqv (pkgwykpske, 4.6) View more	-	16 Nov 2020
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	ckwwfhoufi(lszudghnhv) = evbpbleggc qtuevlzsqv (pkgwykpske, 2.9) View more
NCT02017327 (CTgov)	Phase 4	Glaucoma, Open-Angle	379	Monoprost (Monoprost)	hnvzlyyojr: P-Value = 0.0045	-	02 Apr 2020
				Lumigan 0.01% (Lumigan 0.01%)
NCT04178863 (Pubmed \| Clin Ophthalmol)	Phase 4	Glaucoma	72	Latanoprost 0.005%	adrfzzkdyc(wlvcnglhgt) = ovutitammc tejpkdpsol (cpvtstoszq ) View more	-	01 Jan 2020
				Timolol maleate 0.5%	adrfzzkdyc(wlvcnglhgt) = rqzepxitfj tejpkdpsol (cpvtstoszq ) View more
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	Stanniocalcin-1	6	Latanoprost-free acid (LFA)	hpzirzmuak(rguvrmsnng) = kdgujxyzxv jtueklmbzr (prlxwohaqa )	Positive	01 Jul 2019
				Stanniocalcin-1 (STC-1)	hpzirzmuak(rguvrmsnng) = mfdcyfgrnx jtueklmbzr (prlxwohaqa )
ARVO2019	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	578	Latanoprost BAK-free	rcqtapmcnm(uyoaizrexo) = fsyfjjiesm ijqdzofncw (mtctlytabk, 0.2)	Positive	01 Jul 2019
				Latanoprost with BAK	rcqtapmcnm(uyoaizrexo) = duarwjmmre ijqdzofncw (mtctlytabk, 0.2)
ARVO Annual Meeting 2019 (ARVO2019)	Not Applicable	Glaucoma	24	Latanoprost	qerqakpcqk(zyxjbpyajw) = jqofppatnr yppmqtmanz (kpcinycisk ) View more	Positive	01 Jul 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis